Tvardi Therapeutics (TVRD) Profit After Tax (2013 - 2026)

Tvardi Therapeutics has reported Profit After Tax for 14 years, with the latest figure at -$6.8 million in Q1 2026.

• Quarterly Profit After Tax rose 29.0% year-over-year to -$6.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$15.4 million (up 55.65% YoY) and the FY2025 annual result came in at -$18.2 million, up 38.09% from the prior year.
• Profit After Tax grew to -$6.8 million in Q1 2026 per TVRD's latest filing, from -$7.3 million in the prior quarter.
• Over five years, Profit After Tax peaked at $4.2 million in Q2 2025 and troughed at -$32.3 million in Q4 2023.
• A 5-year average of -$15.3 million and a median of -$9.6 million in 2025 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2022 and 2025: Profit After Tax tumbled 2188.25% in 2022, then jumped 159.74% in 2025.
• Over 5 years, Profit After Tax stood at -$31.7 million in 2022, then dropped by 2.16% to -$32.3 million in 2023, then soared by 60.7% to -$12.7 million in 2024, then surged by 42.86% to -$7.3 million in 2025, then gained by 6.35% to -$6.8 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$6.8 million, -$7.3 million, and -$5.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.